Prostate cancer exploits BRD9-driven metabolic reprogramming to shape the aggressive phenotype

Investigators identified Bromodomain-containing protein 9 (BRD9) as a metabolic checkpoint for reprogramming cell metabolism to support tumor growth and impart a castration-resistant phenotype under metabolic and oxidative stress.